What is the latest price of ponatinib and comparison of drug purchase costs through different channels

Ponatinib (Ponatinib) is a third-generation oral tyrosine kinase inhibitor (TKI), mainly used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients. Because it targets BCR-ABL mutations and is particularly effective in patients with T315I drug-resistant mutations, it is regarded as an important treatment option in clinical practice.

In China, ponatinib is not yet on the market, so patients cannot purchase it through formal channels, and relevant medical insurance reimbursement information is not yet known. This means that if domestic patients need to use the drug, they must obtain it through overseas channels and use it under the guidance of a doctor to ensure the safety and efficacy of the drug.

In overseas markets, the original drug of ponatinib is mainly the Hong Kong version, with each box selling for about more than 30,000 yuan. The price is relatively expensive, and the actual cost of purchasing medicines may fluctuate due to factors such as exchange rates, transportation, and taxes. Patients who use original drugs need to fully assess their financial affordability and formulate a rational medication plan under the guidance of a doctor.

In addition, generic versions of ponatinib are also available overseas. The price of generic drugs in Laos is about more than 700 yuan, and the price of generic drugs in Bangladesh is about more than 1,000 yuan, which is much more affordable than the original drugs. The ingredients of generic drugs are basically the same as those of original drugs, providing a viable option for patients with limited economic conditions. However, they still need to go through formal channels when purchasing to ensure drug quality and safety.

Reference materials:https://www.drugs.com/